Viridian Therapeutics (VRDN) stock
VRDN's Quality Score fell 2 points on Mon, Oct 5, to 0. Closed away from the day's high (2 chart checks stopped).
Follow VRDN's trial news. Pro members can get an alert when Viridian Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
What's next for VRDN, and how long its cash lasts
From Viridian Therapeutics’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.
Next step the company has named
Cash runway
About 11 quarters
Dilution on the horizon
- Shelf registration (S-3ASR, filed Sep 5, 2025)
- At-the-market share sales program (S-3ASR, filed Sep 5, 2025)
Insiders
Chief Legal Officer Jennifer Tousignant sold 14,212 shares on Aug 19. 1 more insider trade this year.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.
- In 24 daysINOInovio Pharmaceuticals
INOINO-3107
- In 35 daysNRXPNRX Pharmaceuticals
NRXPDrug not named
- In 47 daysCAPRCapricor Therapeutics
CAPRDrug not named
Why it's down
Down 48% from its 5-year high in Jan 2023. The S&P 500 rose 90% over the same stretch.
Down more than its industry: the 234 other stocks in it fell a median 5% over the same stretch.
−3Long-term trend below a falling 200-day average, down over one year, down over two years
2 more things pulling VRDN's score down, for Pro members
What's next
Expected to report Thu Nov 5, before the open
After its last 4 reports it closed +12.6% on average, higher 4 of 4 times.
What would turn VRDN's score around: 6 things, for Pro members
Here is what Pro members see.
- Prices refresh every 2.5 seconds during market hours.
- Optional alerts by push, email, or the bell.
- Add it to your Home Screen and it opens like an app.
VRDN has 1 of 14 checks firing
One per group is shown here.
Also on the chart
- RSI 1434.0
- MACD (12, 26, 9)Below signal
- 50-day average$21.95
- 200-day average$22.76
- ADX 1426.4
- Support$18.40
- Resistance$20.00
- Bollinger Bands (20, 2)Inside
- Volume1.4x
How VRDN ranks in Biotech
VRDN is #153 of 300 by Quality Score. The top three are shown with their scores, and more by name.
ONC8/1420
RGEN8/1420
CORT8/1418
VKTXOpen for its score
VNDAOpen for its score
VRTXOpen for its score
WHWKOpen for its score
VRDN1/140
When does VRDN report earnings, and what happens after?
Expected to report Thu Nov 5, before the open (in 30 days). Not yet confirmed by the company.
| Reported | When | Gap | Reaction | 5 sessions |
|---|---|---|---|---|
| Aug 6, 2026Before open | Before open | -0.6% | +6.8% | +8.6% |
| May 5, 2026Before open | Before open | +35.6% | +33.4% | +22.3% |
| Feb 26, 2026Before open | Before open | -6.5% | +1.9% | +5.0% |
| Nov 5, 2025Before open | Before open | +3.1% | +8.3% | +26.1% |
Who is trading VRDN
VRDN insider trades
One insider sold $348K across 2 filings in the last 6 months. No open-market buys on record. The newest:
About Viridian Therapeutics
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
Pro members see every line of every stock's score.
- Real-time prices, no delay
- Every line of VRDN's score, with the points and the reason
- All 14 checks on VRDN and on all 3,243 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on VRDN
Straight Answers
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.
Do I need an account?
Not to start. Tap any green button and you're in, free, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.